Delivering on the potential of Alphabodies
Complix’ main focus is to build a pipeline of Cell Penetrating Alphabodies (CPABs) in cancer and autoimmune disease.
In parallel with its own development activities Complix is keen to work with partners to help deliver the significant potential of its Alphabody platform. Complix expects significant interest from big pharma and biotech companies to develop novel Alphabody-based therapeutics with significant commercial potential, given Alphabodies’ potential to develop novel drugs for a broad range of diseases for which there are currently no therapeutic options.
Strategic collaboration with Merck to develop Alphabodies against cancer targets
Complix has entered into a strategic drug discovery collaboration with Merck & Co., Inc. to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer.
Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver CPABs against up to two intracellular cancer targets. Merck will fund the research activities at Complix and has an option to the exclusive, worldwide rights for any of the resulting compounds. Complix is entitled to receive an upfront payment and potential development milestones of up to $280 million, as well as tiered royalties.